-
TScan reaches FDA agreement on pivotal study design for TSC-101
-
TScan Therapeutics, Inc. (TCRX) Tops Q2 EPS by 5c
-
Tscan Therapeutics Inc (TCRX) PT Lowered to $10 at H.C. Wainwright
-
TScan Therapeutics, Inc. (TCRX) Tops Q1 EPS by 54c
-
H.C. Wainwright Reiterates Buy Rating on Tscan Therapeutics Inc (TCRX)
-
TScan Therapeutics, Inc (TCRX) Files $300M Mixed Shelf
-
TScan Therapeutics, Inc. (TCRX) Misses Q4 EPS by 1c
-
TScan Therapeutics, Inc (TCRX) Announces 7.5M Share Offering at $4/sh
-
TScan Therapeutics, Inc. (TCRX) Tops Q3 EPS by 6c
-
TScan Therapeutics, Inc. (TCRX) Reports In-Line Q2 EPS
-
TScan Therapeutics (TCRX) Announces Updates to its Board of Directors

